How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Lenalidomide is not recommended, within its marketing authorisation, as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

1.2 This recommendation is not intended to affect treatment with lenalidomide that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

There is currently no maintenance treatment for newly diagnosed multiple myeloma in people who have had an autologous stem cell transplant. The condition is usually monitored until it gets worse.

Clinical trial results show that, compared with monitoring alone, lenalidomide increases how long people live and extends the time before the condition gets worse.

The cost-effectiveness estimates are uncertain. This is because of limitations in the cost-effectiveness model, and because the model might not reflect what happens in the NHS in England. Therefore, lenalidomide is not recommended for use in the NHS for this indication.